FORE Biotherapeutics Completes the FDA Hat Trick for Plixorafenib in Brain Cancer
Plixorafenib just became the first targeted therapy to earn Breakthrough Therapy Designation in high-grade glioma — adding to Fast Track and Orphan Drug status.
Category Highly Important
Ray Therapeutics Lands FDA RMAT Designation for Optogenetic Vision Therapy RTx-015
A single intravitreal injection that reprograms retinal cells to detect light. The FDA just gave it the fast lane.
Adcytherix Doses First Patient Just 21 Months After Incorporation
From founding to first patient in under two years — Adcytherix just entered the clinic with ADCX-020 after raising €135M. Its founders previously built the ADC company Lilly acquired.
Eli Lilly Buys Centessa for $6.3 Billion to Own the Orexin Franchise
Lilly didn't just buy a drug — they bought an entire orexin franchise. The $6.3B Centessa deal includes three OX2R agonists across clinical and preclinical stages.
TippingPoint Biosciences Raises $4.5M Seed to Target Pediatric Brain Cancer
TippingPoint just closed an oversubscribed $4.5M seed to go after DIPG — the deadliest childhood brain tumor — with a first-in-class epigenetic approach.
AI In Dermatology? Yeah, That’s A Thing Now. Thanks To Enveda Biosciences.
Enveda's ENV-294 hit 85% EASI reduction and 100% EASI-50 in Phase 1b for atopic dermatitis — and it's oral, first-in-class, and derived from plants.
Alltrna Sends the First tRNA Therapeutic Into Human Testing
Alltrna's AP003 just became the first tRNA-based drug to enter clinical trials — a milestone for an entirely new modality.
Stop Inhibiting. Start Destroying.
TRIANA Biomedicines doses the first patient with TRI-611, a brain-penetrant molecular glue degrader that eliminates ALK fusion proteins — not just blocks them.
Molecular Glues Were Discovered by Accident. Not Anymore.
Molecular glues are biotech's hottest modality and its hardest to design rationally. Ternary thinks AI can change that.
What If B-Cell Depletion Didn’t Need T Cells at All?
Commit Biologics raises €21.5M to weaponize the complement system against B cells — no cytokine storm required.